$VVX

V2X (VVX) Could Be 19% Undervalued As Marine Corps Deal Expands Defense Push

V2X (VVX) secured a $19M contract with the U.S. Marine Corps for counter drone vehicles. Its share price has fallen 9.9% in 30 days but is up 30.6% year-to-date. Analysts suggest it may be 19% undervalued at $72.56, with a fair value target of $89.09, citing strong backlog and industry trends.

Original reporting
Published Sep 11, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 6:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$VVX
Bullish
medium confidence
Mentioned
$VVX
Relevance
7/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$VVXBullishMed
01

Why it matters

The new contract could narrow the valuation gap cited by analysts, but the modest size limits upside.

02

Market read

A new defense contract adds incremental revenue to V2X, modestly supporting its valuation case.

03

What to watch

Potential execution risk if the Marine Corps program faces delays or budget cuts.

Relevance 7/10Novelty 7/10Timing: contract announced on Sep 11 2026

Background

V2X is a mid‑cap defense contractor listed on NYSE; the article provides a brief valuation narrative and highlights recent price performance.

Company-level read

Ticker impact

$VVXBullishMedium confidence
Context

V2X secured a $19 million indefinite delivery, indefinite quantity contract from the U.S. Marine Corps for its Tempest counter‑drone vehicles and support services.

Expected impact

Potential modest upside of 3‑5% if the market prices in the new revenue.

Evidence & confidence

The deal size is modest relative to V2X's $11.3 B backlog, but it reinforces the company's defense pipeline and could improve margins as execution matures.

Market effects

Adds to defense sector demand outlook, especially for counter‑drone systems.

Supports U.S. defense contractors competing for Marine Corps spend.

Limited to defense supply chain; unlikely to affect broader markets.

Counterpoint

The $19 M contract is small relative to V2X's backlog; price may already reflect the news.

Key entities

  • V2X

    Defense contractor focused on counter‑drone systems.

  • U.S. Marine Corps

    Awarded the $19 M contract.

Related articles

$VVXMed

VVX Looks 18.1% Overvalued on GF Value™

V2X Inc. (NYSE: VVX) secured a $46M contract for the U.S. Air Force's LRSO cruise missile program. GF Value™ suggests VVX is 18.1% overvalued, trading at $72.96 vs. an estimated intrinsic value of $61.78. The company has a GF Score™ of 69/100, with strong profitability and growth but weak momentum. Insiders have sold $487.9M in shares over the past year, with no purchases.

$VVXMed

V2X wins position on $46M Air Force missile contract

V2X Inc. (NYSE:VVX) secured a $46M contract for the U.S. Air Force's Long Range Standoff cruise missile program, supporting B-52 Stratofortress integration. The contract is part of the LRSO program, replacing the current Air-Launched Cruise Missile. V2X provides engineering and manufacturing services for defense and national security.

$VVXMed

V2X Awarded Position on $46 Million U.S. Air Force Contract Supporting B-52 Long Range Standoff Cruise Missile Program

V2X Inc. (NYSE: VVX) has secured a $46 million contract with the U.S. Air Force for the Long Range Standoff (LRSO) cruise missile program, supporting the B-52 Stratofortress. The contract involves producing carriage equipment for the LRSO weapon system, reinforcing V2X's role in defense modernization. The company aims to enhance mission readiness and national security.

$VVXHighAI 8/10

V2X (VVX) Lands $500 Million Air Force Deal Following A Fair Value Debate

V2X (VVX) secured a $500M contract with the US Air Force for C-12 Huron fleet support until 2031. The company reported double-digit growth in recent results, providing long-term revenue visibility. Shares are up 36.93% year-to-date but down 10% over the past quarter. Analysts estimate a fair value of $89.09, suggesting undervaluation at the current price of $76.08.